Abstract
Although there is a paucity of empirically based studies on the use of psychotropic drugs in the treatment of childhood disorders, medication is often considered an integral part of a treatment plan for children with psychiatric and behavioral disorders (Olfson, Pincus, & Sabshin, 1994). However, it is important to remember that medication is typically used as only one component of a broad therapeutic approach to alleviate psychiatric symptoms in children. For psychiatric problems, such as anxiety or depression, medication provides symptomatic relief, allowing the child to function more fully at school and at home. In general, medication should be used to improve the child’s general functioning and quality of life rather than strictly for reducing undesirable behaviors or symptoms (Singh, 1995). Further, although medication may relieve the child’s symptoms of psychiatric illness, it does not remove vulnerability to its recurrence because the environmental and constitutional stressors that gave rise to the illness are not affected by the medication.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Achenbach, T. M. (1991). Manual for the CBCL/4-18 and Profile. Burlington: Department of Psychiatry, University of Vermont.
Alessi, N., Naylor, M. W., Ghaziuddin, M., & Zubieta, J. K. (1994). Update on lithium carbonate therapy in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 291–304.
Aman, M. G. (1993). Monitoring and measuring drug effects. II. Behavioral, emotional, and cognitive effects. In J. S. Werry & M. G. Aman (Eds.), Practitioner’s guide to psychoactive drugs for children and adolescents (pp. 99–159). New York: Plenum Press.
Baldessarini, R., & Frankenburg, F. R. (1991). Clozapine: A novel antipsychotic agent. New England Journal of Medicine, 324, 746–754.
Ballenger, J. C., & Post, R. M. (1980). Carbamazepine in manic-depressive illness: A new treatment. American Journal of Psychiatry, 137, 782–790.
Barkley, R. A. (1990). Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York: Guilford Press.
Barkley, R. A., DuPaul, G. J., & Costello, A. (1993). Stimulants. In J. S. Werry & M. G. Aman (Eds.), Practitioner’s guide to psychoactive drugs for children and adolescents (pp. 205–237). New York: Plenum Press.
Carpenter, R. O., & Vining, E. P. G. (1993). Antiepileptics (anticonvulsants). In J. S. Werry & M. G. Aman (Eds.), Practitioner’s guide to psychoactive drugs for children and adolescents (pp. 321–346). New York: Plenum Press.
Clein, P. D., & Riddle, M. A. (1995). Pharmacokinetics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 4, 59–75.
Conners, C. K. (1990). Conners’ Rating Scales Manual, Conners’ Teacher Rating Scales, Conners Parent Rating Scales. Instruments for use with children and adolescents. North Tonawanda, NY: Multi-Health Systems.
Dingemanse, J., Danhof, M., & Breimer, D. D. (1988). Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: An overview. Pharmacology and Therapeutics, 38, 1–52.
Ellis, C. R., Singh, Y. N., & Singh, N. N. (1997). Use of behavior-modifying drugs. In N. N. Singh (Ed.). Prevention and treatment of severe behavior problems: Models and methods in developmental disabilities (pp. 149–176). Monterey, CA: Brooks/Cole.
Evans, R. W., Clay, T. H., & Gualtieri, C. T. (1987). Carbamazepine in pediatric psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 2–8.
Evans, W. E., Schentag, J. J., & Jusko, W. J. (1986). Applied pharmacokinetic principles of therapeutic drug monitoring (2nd ed. ) San Francisco: Applied Therapeutics.
Green, W. H. (1995). Child and adolescent clinical psychopharmacology (2nd ed.). Baltimore: Williams & Wilkins.
Greenblatt, D. J., & Shader, R. I. (1987). Introduction: Pharmacokinetics in clinical psychiatry and psychopharmacology. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (p. 1339). New York: Raven Press.
Handen, B. L., Feldman, H., Gosling, A., Breaux, A., & McAuliffe, S. (1991). Adverse side effects of Ritalin among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 241–245.
Institute of Medicine (1990). Research on children and adolescents with mental, behavioral, and developmental disorders. Bethesda: National Institute of Mental Health.
Janicak, P. G., Davis, J. M., Preskorn, S. H., & Ayd, F. J. (1993). Principles and practice of psychopharmacology. Baltimore: Williams & Wilkins.
Kalow, W. (1990). Pharmacogenetics: Past and future. Life Sciences, 47, 1385–1397.
Kutcher, S. P. (1997). Child and adolescent psychopharmacology. Philadelphia: Saunders.
Lieberman, J. A., Kane, J. M., & Johns, C. A. (1989). Clozapine: Guidelines for clinical management. Journal of Clinical Psychiatry, 50, 329–338.
McElroy, S. L., Keck, P., & Pope, H. G. (1987). Sodium valproate: Its use in primary psychiatric disorders. Journal of Clinical Psychopharmacology, 7, 16–24.
Moerman, D. E. (1979). Anthropology of symbolic healing. Currents in Anthropology, 20, 59–80.
Nebert, D. W, & Weber, W. W. (1990). Pharmacogenetics. In W. B. Pratt & P. Taylor (Eds.), Principles of drug action (pp. 469–531). New York: Churchill Livingstone.
Olfson, M., Pincus, H. A., & Sabshin, M. (1994). Pharmacotherapy in outpatient psychiatric practice. American Journal of Psychiatry, 151, 580–585.
Paxton, J. W., & Dragunow, M. (1993). Pharmacology. In J. S. Werry & M. G. Aman (Eds.), Practitioner’s guide to psychoactive drugs for children and adolescents (pp. 23–55). New York: Plenum Press.
Popper, C. W. (1995). Balancing knowledge and judgement: A clinician looks at new developments in child and adolescent psychopharmacology. Child and Adolescent Psychiatric Clinics of North America, 4, 483–513.
Post, R. M. (1987). Mechanisms of action of carbamazepine and related anticonvulsants in affective illness. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 567–594). New York: Raven Press.
Remschmidt, H. (1976). The psychotropic effects of carbamazepine in non-epileptic patients, with particular reference to problems posed by clinical studies in children with behavioral disorders. In W. Birkmayer (Ed.), Epileptic seizures, behavior, pain (pp. 253–258). Bern: Huber.
Riddle, M. A., Nelson, J. C., Kleinman, C. S., Rasmusson., A., Leckman, J. F., King, R. A., & Cohen, D. J. (1991). Sudden death in children receiving Norpramin: A review of three reported cases and commentary. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 104–108.
Singh, N. N. (1995). Moving beyond institutional care for individuals with developmental disabilities. Journal of Child and Family Studies, 4, 129–145.
Singh, N. N., & Aman, M. G. (1990). Ecobehavioral assessment of pharmacotherapy. In S. Schroeder (Ed.), Ecobehavioral analysis in developmental disabilities (pp. 182–200). Berlin: Springer-Verlag.
Singh, N. N., & Ellis, C. R. (1998). Pharmacological therapies. In A. S. Bellack & M. Hersen (Ser. Eds.), T. Ollendick (Vol. Ed.), Comprehensive clinical psychology: Vol. 4. Children and adolescents: Clinical formulation and treatment (pp. 267–293). New York: Elsevier Science.
Singh, N. N., Ellis, C. R., & Axtell, P. K. (1998). Psychopharmacology and steady-state behavior. In J. K. Luiselli & M. J. Cameron (Eds.), Beyond consequences: Antecedent control approaches for the behavioral support of persons with developmental disabilities (pp. 137–162).Baltimore: Paul H. Brookes.
Singh, N. N., Parmelee, D. X., Sood, A., & Katz, R. C. (1993). Collaboration of disciplines. In J. L. Matson (Ed.), Handbook of hyperactivity in children (pp. 305–322). Boston: Allyn & Bacon.
Sood, A., & Singh, N. N. (1996). Diagnostic instruments. In D. X. Parmelee (Ed.), Child and adolescent psychiatry (pp. 19–31). St. Louis: Mosby.
Sprague, R. L., & Gadow, K. D. (1976). The role of the teacher in drug treatment. School Reviews, 85, 109–140.
Towbin, K. E. (1995). Evaluation, establishing the treatment alliance, and informed consent. Child and Adolescent Psychiatric Clinics of North America, 4, 1–14.
Viesselman, J. O, Yaylayan, S., Weiler, E. B., & Weller, R. A. (1993). Antidysthymic drugs (antidepressants and antimanics). In J. S. Werry & M. G. Aman (Eds.), Practitioner’s guide to psychoactive drugs for children and adolescents (pp. 239–268). New York: Plenum Press.
Walkup, J. T. (1995). Clinical decision making in child and adolescent psychopharmacology. Child and Adolescent Psychiatric Clinics of North America, 4, 23–40.
Zhou, H. H., Koshakji, R. P., Silberstein, D. J., Wilkinson, G. P., & Wood, A. J. (1989). Racial differences in drug response: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. New England Journal of Medicine, 320, 565–570.
Zorumski, C. F., & Isenberg, K. E. (1991). Insights into the structure and function of GABA-benzodiazepine receptors: Ion channels and psychiatry. American Journal of Psychiatry, 148, 162–163.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ellis, C.R., Singh, N.N. (1999). Psychopharmacological Approaches. In: Russ, S.W., Ollendick, T.H. (eds) Handbook of Psychotherapies with Children and Families. Issues in Clinical Child Psychology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4755-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4755-6_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7156-4
Online ISBN: 978-1-4615-4755-6
eBook Packages: Springer Book Archive